Skip to main content

Table 4 Threshold Evaluation of hsTnI

From: Randomized study of doxorubicin-based chemotherapy regimens, with and without sildenafil, with analysis of intermediate cardiac markers

  

Pre hsTnl

Post hsTnl

Day 2 hsTnl

≤10 pg/mL

> 10 pg/mL

≤10 pg/mL

> 10 pg/mL

≤10 pg/mL

> 10 pg/mL

LVEF Change

 N

<  10% (N = 17)

10

7

10

7

11

6

 Row %

58.82

41.18

58.82

41.18

64.71

35.29

 Col %

76.92

63.64

76.92

63.64

73.33

66.67

 N

≥ 10% (N = 7)

3

4

3

4

4

3

 Row %

42.86

57.14

42.86

57.14

57.14

42.86

 Col %

23.08

36.36

23.08

36.36

26.67

33.33

 

Total

13

11

13

11

15

9

Strain Group

 N

< −17 (N = 10)

7

3

6

4

7

3

 Row %

70

30

60

40

70

30

 Col %

87.5

37.5

85.71

44.44

70

50

 N

≥ − 17 (N = 6)

1

5

1

5

3

3

 Row %

16.67

83.33

16.67

83.33

50

50

 Col %

12.5

62.5

14.29

55.56

30

50

 

Total

8

8

7

9

10

6